camrelizumab,toripalimab
coherus,junshi biosciences,jiangsu hengrui pharmaceuticals
['toripalimab', 'camrelizumab']
excellent talk (as always!!) by neil mehta on post transplant hcc recurrence risk and management, including controversial role of post lt immunotherapy #ddw2023 
transplant hepatologist and researcher @ UT Southwestern; interest in liver cancer, health disparities 👩🏼‍💻; Cleveland sports fan 🤷🏼‍♀️; opinions mine